Psychedelic drug developer atai Life Sciences has announced a strategic investment in its British peer, Beckley Psytech.The investment will see atai gain exposure to Beckley’s two primary clinical programs: its intranasal 5-MeO-DMT candidate (BPL-003) and intravenous psilocin (ELE-101).The investment will take the form of a $40m direct investment into the company, with an additional $10m in…
